The effort to develop psychedelic therapies took a hit earlier this month when the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy, a blow that was quickly followed by the retraction of three Lykos research papers and the slashing of 75% of the biotech’s workforce.

Foreign-made drugs are often unavailable in Japan due to the country’s approval process, which requires clinical trial data from Japanese patients. To address this issue, known as “drug loss,” Japanese technology company Fujitsu is partnering with American start-up Paradigm Health to attract global clinical trials to the island nation.

Illumina has secured an FDA approval to bring its pan-cancer tissue profiling test to U.S. shores.

Neurocrine Biosciences has achieved its hoped-for profile in a phase 2 schizophrenia trial, delivering its targeted level of efficacy with a lower rate of gastrointestinal adverse events than Bristol Myers Squibb’s KarXT. But the biotech only saw efficacy at the lowest dose—the three higher doses all failed.

Curi Bio is on the move. The Seattle-based company has signed a seven-year lease for a roomy, 13,942-square-foot space overlooking Puget Sound in Washington, with plans to move in by early 2025.

The FDA has cleared its first automated insulin pump for adults with Type 2 diabetes, with Insulet’s Omnipod 5 delivery system opening the door to a population of more than 6 million people.

Indivior is picking up a small molecule allosteric modulator designed to treat substance use disorder from Addex Therapeutics, providing the latter the chance to make up to $300 million in biobucks, plus royalties.

Molecular Partners has identified “suboptimal exposure” to its tetra-specific T-cell engager as the potential cause of the limited response rate in its early-phase trial, prompting the Swiss biotech to change the protocol to try to dial up the impact of the compound.

China’s Duality Biotherapeutics has filed (PDF) paperwork for a Hong Kong IPO, seeking an undisclosed sum to power a broad pipeline of antibody-drug conjugates toward approval. The filing extends the recent flurry of IPO activity beyond the U.S. and into Asia.

Vaderis Therapeutics’ goal to develop the first drug aimed specifically at a certain rare blood vessel disorder came one step closer today with the news that the therapy is safe and reduced nosebleeds.